CytoNiche expands FDA and China filings for 3D RecomTrix microcarriers

CytoNiche Biotech said Aug. 25, 2026, that it has added new U.S. and China regulatory filings for its 3D RecomTrix recombinant collagen microcarriers, extending the product’s compliance footprint for cell manufacturing. The move could help the Singapore-based company sell defined, animal-free inputs to developers of cell and gene therapies at clinical and commercial scale.

Why it matters: - The filings strengthen the regulatory case for 3D RecomTrix CW01 as a defined, animal-free microcarrier for scalable cell manufacturing. - Cell and gene therapy makers face growing pressure to use raw materials with better definition, traceability and process consistency. - A broader regulatory dossier can make it easier for biopharma developers to adopt CytoNiche’s materials in clinical and commercial workflows.

What happened: - CytoNiche Biotech said Aug. 25, 2026, that it expanded the global regulatory portfolio for its 3D RecomTrix™ recombinant collagen microcarriers, known as CW01. - The company filed a Type II DMF, DMF043937, and a Type IV DMF, DMF043963, with the FDA Center for Drug Evaluation and Research. - CytoNiche also filed a Type II Master File, MF32742, with the FDA Center for Biologics Evaluation and Research. - CW01 already holds an NMPA Center for Drug Evaluation excipient registration, F20250000786.

The details: - CW01 is made from GMP-grade recombinant collagen. - The material is designed as a defined, animal-free substrate for 3D cell expansion. - The microcarriers have an elastic, highly porous 3D structure with more than 90% porosity and a high specific surface area. - CytoNiche says the structure provides more surface for cell attachment while improving bioreactor volume use. - CW01 uses dissolvable microcarrier technology to support cell expansion and downstream harvesting in one workflow. - The elastic architecture is designed to protect cells during dynamic cultivation. - After expansion, the dissolvable structure enables gentle, enzyme-free cell harvesting. - CW01 is pre-sterilised by radiation and disperses upon hydration. - That design supports automated and closed-system manufacturing processes.

Between the lines: - The new filings extend CytoNiche’s regulatory reach beyond its flagship 3D TableTrix™ Microcarrier Series. - The TableTrix line already includes FDA DMFs DMF037798 and DMF035481, FDA Master File MF29721, and two NMPA excipient registrations, F20200000496 and F20210000003. - Building a larger filing portfolio can help CytoNiche look more established to drug developers weighing supply chain and compliance risk. - The regulatory strategy also mirrors a broader industry shift toward standardized, scalable and better documented manufacturing inputs.

What's next: - CytoNiche is positioning 3D RecomTrix CW01 for broader use in biopharmaceutical manufacturing markets. - The company is also continuing to expand its 3D cell manufacturing platform for cell and gene therapy applications. - CytoNiche says its goal is to support more efficient and accessible pathways to cell-based therapies worldwide.

The bottom line: - CytoNiche is turning regulatory paperwork into a commercial moat for its microcarrier platform. - The company now has a stronger FDA and China foundation behind a product aimed at standardized, scalable cell manufacturing.

More information